Skip to main content
Clinical Trials/NCT04522037
NCT04522037
Unknown
Not Applicable

Retrospective Study of the Measurement of the Efficacy of MORPHINE in the Early Management of Dyspnea in COVID-19 Positive Patients With Moderate to Severe Impairment Without Objective of Resuscitation Management (Level of Care 3 and 4) at the Hospices Civils of Lyon

Hospices Civils de Lyon3 sites in 1 country200 target enrollmentJune 1, 2020

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Patients Hospitalized in the Hospices Civils of Lyon
Sponsor
Hospices Civils de Lyon
Enrollment
200
Locations
3
Primary Endpoint
Title : Reduction of respiratory rate between Hour 0 and Hour 12 at initiation of morphine treatment
Last Updated
5 years ago

Overview

Brief Summary

Morphine is used in the treatment of dyspnea and polypnea with a proven benefit on the improvement of these symptoms, both etiologically and symptomatically. This medication is used in particular in palliative care for this type of symptom.

The Sars CoV2 viral pneumonia table can lead to respiratory distress. In patients with moderate to severe impairment without goal of resuscitation (level of care 3 and 4), the introduction of morphine may sometimes be necessary to relieve respiratory symptoms. These also lead to major exhaustion which can worsen the clinical picture. However, the prescription of morphine is not systematic in front of a respiratory distress table.

The investigators hypothesized that early treatment with morphine lead to a better management of dyspnea, quality of live and survival in COVID-19 positive participants patients when there is not resuscitation objective management (level of care 3 and 4).

The objective is to measure the efficacy of morphine in the early management of dyspnea, quality of life and survival in COVID-19 positive participants patients treated in the Hospices Civils of Lyon during COVID-19 pandemic.

Registry
clinicaltrials.gov
Start Date
June 1, 2020
End Date
February 2021
Last Updated
5 years ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Age over 18 years.
  • Having had a Covid-19 respiratory disease confirmed by PCR or TDM or anamnestic criterion for patients living in communities for the elderly (respiratory symptomatology suggestive and at least 3 cases confirmed in the living environment).
  • Having had respiratory severity criteria: respiratory distress syndrome including FR\> 25 / min and oxygen-demand\> 4 L / min to maintain a SpO2\> 90% at inclusion.
  • Having had a defined level of care after collegial discussion notified in the file rejecting the external cardiac massage and admission to the intensive care unit (Level 3 and 4 on the protocols of the Hospices Civils de Lyon).
  • Collection of non-opposition

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

Title : Reduction of respiratory rate between Hour 0 and Hour 12 at initiation of morphine treatment

Time Frame: Hour 0 and Hour 12 after initiation of morphinic treatment

The respiratory rate is analyzed at Hour 0 and Hour 12 by a scope.

Study Sites (3)

Loading locations...

Similar Trials